Bluetooth Marktstudie – Gerätenetzwerke am schnellsten wachsender Lösungsbereich – Hartware hartware.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hartware.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BEDMINSTER, N.J., May 4, 2021 /PRNewswire/ Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, recently named Ernesto Aycardi, M.D., to the position of Chief Development Officer on April 26, and is welcoming Eslie Dennis, M.D., MBChB, FCP(SA) in the role of Chief Medical Officer today. These appointments come at a pivotal time for the company, as the North America region aims to realize the full potential of its existing commercial portfolio and compounds being investigated in the pipeline. In particular, the company is working on plans to advance KW-6356, a selective antagonist of adenosine A2A receptors, and KHK4083, an Anti-OX40 Fully Human Antibody, and is also collaborating with partner MEI Pharma to complete the pivotal study and shape a broader development program for zandelisib, a selective PI3Kδ inhibitor.
Key Stakeholders
Downstream vendors and end-users
Drugs for Central Nervous System industry associations and research organizations
Product managers, Drugs for Central Nervous System industry administrator, C-level executives of the industries
Market Research and consulting firms
Reasons to Purchase this Report
Analyzing the outlook of the market with the recent trends and Porters five forces analysis
Market dynamics which essentially consider the factors which are impelling the present market scenario along with growth opportunities of the market in the years to come
Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market
Ethypharm establishes direct presence in Italy
USA - English
Share this article
SAINT-CLOUD, France, April 23, 2021 /PRNewswire/
Ethypharm announces today that it now has a fully established affiliate to operate directly in Italy, the third largest pharmaceutical market in Europe. Under the leadership of Bruno Rago, Ethypharm Italy will reinforce the group s commercial footprint in Europe, notably in its core therapeutic area of the Central Nervous System.
Founded in 1977 in France, Ethypharm is a specialty pharmaceutical company with solid roots in Europe and China. After its establishment in the United Kingdom and Germany in 2015, the addition of a direct presence in Italy is a major milestone to strengthen the group s commercial platform in Europe. Ethypharm Italy Srl is headquartered in Padova and will serve both the hospital and retail pharmacy channels.
Ethypharm establishes direct presence in Italy finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.